Welcome to our dedicated page for Shineco news (Ticker: SISI), a resource for investors and traders seeking the latest updates and insights on Shineco stock.
Shineco, Inc. (SISI) generates news across several intersecting themes in health technology, regenerative medicine, diagnostics, and capital markets. Company announcements describe a business that combines innovative diagnostic medical products and devices with induced pluripotent stem cell (iPSC) platforms, biological cell storage and applications, and emerging blockchain-based frameworks for cell asset digitalization. News about Shineco often highlights how these elements interact within its broader strategy to provide health and medical products and services.
Recent press releases have focused on Shineco’s expansion into regenerative medicine through its majority-owned subsidiary InfiniClone Limited, which concentrates on iPSC technology and regenerative medicine applications. Other updates have described the role of Xi'an Dong'ao Health Management Co., Ltd. in GMP-compliant biostorage and clinical cell applications, as well as the company’s efforts to build a biological cell digital division to connect cell assets with blockchain systems. These developments are presented as part of a vertical ecosystem in the biological cell sector.
Investors following SISI news will also see coverage of Shineco’s acquisition activity, such as the purchase of a controlling interest in InfiniClone and the agreement to acquire a majority stake in FuWang (HK) International Company Limited, a medical device company. Additional news items have addressed corporate actions like a reverse stock split, capital-raising transactions through share offerings, and management-led open-market stock purchase plans, as well as updates on Nasdaq listing compliance and delisting proceedings.
This news page aggregates Shineco’s press releases and related coverage so readers can review developments in its diagnostics and medical devices business, regenerative medicine initiatives, biological cell and blockchain projects, acquisitions, financing activities, and listing status. For those tracking SISI, the news flow provides insight into how the company describes its evolving business mix and strategic priorities in the health and medical sector.
Shineco, Inc. (NASDAQ: SISI) has launched its redesigned website to enhance user experience and inform stakeholders about its expansion into the life science industry. The modernized site features user-friendly navigation and easy access to corporate information, including management details and SEC filings. CEO Jennifer Zhan emphasized that the website revamp represents a significant step in showcasing the company's latest developments to shareholders and the investment community. This initiative reflects Shineco's commitment to improving brand awareness and market presence.
Shineco, Inc. (NASDAQ: SISI) announced a strategic cooperation agreement with Beijing Xihuan Psychological Consulting Co., Ltd. on February 21, 2022. The partnership aims to establish an industry-university-research-medical collaborative platform focusing on the psychological rehabilitation of tumor patients. Both companies will conduct research on mental health interventions, enhancing Shineco's tumor clinical treatment system. This initiative seeks to improve early diagnosis and treatment rates for tumor diseases by integrating psychological health into comprehensive care.
On February 16, 2022, Shineco, a producer of herbal medicines and biotech products, signed a strategic cooperation agreement with Beijing Jinshengyun Pharmaceutical Technology Co., Ltd. (JSY). The partnership aims to enhance R&D in innovative drugs and medical devices. JSY specializes in clinical trials and regulatory compliance, contributing expertise to the establishment of Shineco's pharmaceutical R&D center. This collaboration aligns with China's healthcare development goals, intending to seize market opportunities in the pharmaceutical industry.
Shineco (SISI) announced a partnership with Weifang Jianyi Medical Devices to jointly manufacture nuclear medicine imaging devices, including PET, PET-CT, and PET-MRI. This collaboration aims to produce up to 100 devices in 2022, each projected to cost between USD $1.10 million and $1.25 million. The partnership will leverage WJM's technological expertise, addressing the high demand for advanced imaging solutions in China, which is currently dominated by foreign firms like GE and Philips. The devices will be distributed to over 100 specialized hospitals for tumor diagnosis in China.
Shineco, Inc. (NASDAQ: SISI) has appointed Professor Qiyin Sun as Chief Medical Consultant to spearhead its tumor treatment research and innovation. Professor Sun, a prominent figure with over 30 years in medical R&D, has notable achievements in nuclear medicine and medical imaging. His expertise includes the development of radiodynamic therapy devices, certified by both the CFDA and FDA. Shineco's CEO, Jennifer Zhan, expressed confidence that Professor Sun's extensive experience will enhance the company’s R&D capabilities, aiming to improve diagnosis and treatment technologies for tumor patients.
Shineco, Inc. (NASDAQ: SISI) has announced its acquisition of a 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd. for approximately $5.6 million, paid with 700,551 shares at $8 each. This strategic move aims to accelerate Shineco's entry into the digital healthcare sector and enhance its services through XPYK's established medical platform. The deal is expected to close within 60 days, pending customary conditions. Shineco plans to leverage this acquisition to improve health management services and capture growth opportunities in China's expanding digital medical market.
Shineco, Inc. (NASDAQ: SISI) has entered into a securities purchase agreement to sell $2 million of its common stock at a price of $6.8546 per share to GHS Investments, LLC. The net proceeds will be utilized for acquiring biotech research companies, working capital, and general corporate purposes. This offering is conducted under an effective shelf registration statement with the SEC. Shineco is focused on producing Chinese herbal medicines and organic agricultural products, headquartered in Beijing.
Shineco, Inc. (NASDAQ: SISI) announced a potential acquisition of at least 51% equity interest in Xiang Peng You Kang (Beijing) Technology Co., Ltd. (XPYK) through non-binding framework agreements dated November 18, 2021. This strategic move aims to enhance Shineco's integrated medical and healthcare services, leveraging XPYK’s robust medical service platform. The acquisition is expected to facilitate digital transformation and broaden medical offerings across various demographics. The transaction's completion is contingent on due diligence and other customary closing conditions.
Shineco, Inc. (NASDAQ: SISI) announced a Memorandum of Understanding (MOU) to negotiate the acquisition of Dragon Pride Limited, a Hong Kong-based medical aesthetic service provider. This exclusive 90-day window aims to secure either 100% or at least 50% equity interest in Dragon Pride. With China's medical aesthetic market projected to exceed $75 billion by 2022, CEO Jennifer Zhan highlighted potential profitability from new centers. If successful, the acquisition could generate annual net profits of at least RMB 100 million.